Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exubera’s Post-Marketing Safety Program Is Industry Model – Pfizer’s Ryder

Executive Summary

Pfizer's proposed post-marketing studies for the inhaled insulin therapy Exubera exemplify the type of risk management programs FDA should encourage industry to conduct, Pfizer Clinical R&D Senior VP Steven Ryder told an Institute of Medicine committee on Jan. 19

You may also be interested in...



Exubera Education, Complicated Manufacturing Impacting Launch Timeline

Pfizer's mid-year launch timeline for its inhaled insulin therapy Exubera is influenced by the need to educate physicians, complex supply chain issues and reimbursement discussions, Pfizer co-development partner Nektar suggested

Pfizer Exubera Has Mid-Year Launch Trigger, Heavy Dose Of Instructions

Marketing of Pfizer's inhaled insulin Exubera for treatment of adult diabetes mellitus is expected to begin by the end of August

Phase IV Studies Need Greater Input From FDA, Industry Tells IoM Panel

Drug manufacturers need more clarity from FDA regarding post-marketing studies, industry representatives told the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System

Related Content

UsernamePublicRestriction

Register

PS046780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel